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Identity 
Other names: hsa-mir-126; microRNA 126; miR-126; 
MIRN126; miRNA126 
HGNC (Hugo): MIR126 
Location: 9q34.3 
Note: The MiRNA126 are located in intron 7 of the 
epidermal growth factor (EGF)-like-domain, multiple 7 
(EGFL7) gene. In addition, the antisense sequence to 
MIR126 within the hairpin pre-miRNA is also 




Stem loop structure of MiR-126. 
Description 
MiRNAs can be located within their own open reading 
frame (ORF) or within the intron of a host gene. Those 
miRNAs that are located within an intron are dependent 
on the transcriptional regulation of its host gene. I  the 
human genome, miR-126 is found on chromosome 9 
within intron 7 of the EGFL7 gene. An alternative miR-
126 transcript from this region has also been report d 
and is designated miR-126*. Notably, EGFL7 
expression is undetectable in normal brain tissue but is 
deregulated in malignant glioblastoma tumor cells as 
well as vascular endothelium cells within the tumor 
(Huang et al., 2010). EGFL7 is also secreted by 
endothelium and regulates angiogenesis. Recent studie  
demonstrate that both miR-126 and its host gene 
EGFL-7 harbor CpG islands invoking epigenetic 
regulation as one potential mechanism for the observed 
deregulation of miR-126 in both solid and hematologic 
malignancies (Saito et al., 2009). 
Transcription 
MiRNAs are transcribed as a longer primary mRNA 
transcript which is called a pri-miR. The pri-miRs are 
processed mRNA molecules containing a 5' cap and a 
poly A tail and can range from hundred to thousand 
nucleotides (Nana-Sinkam et al., 2009). Currently the
pri-miR for miR-126 is unknown. In the nucleus, the 
processing of the pri-miRs by the RNase enzyme, 
Drosha, to a smaller pre-miR molecule occurs (Nana-
Sinkam et al., 2009). The pre-miR forms a stem loop 
structure to facilitate its transport to the nucleus. For 
miR-126, it is processed to an 85 nucleotide pre-miR 
that is then transported to the cytoplasm. Once in the 
cytoplasm, the pre-miR is incorporated in the RNA-
inducible silencing complex (RISC). The RISC 
contains an RNase III endonuclease, Dicer, which 
further cleaves the pre-miR to the mature miRNA and
minor antisense miRNA. 





The mature sequence for miR-126 is 52-
ucguaccgugaguaauaaugcg-73. 
Minor miRNA sequence: 
In some cases, the antisense sequence to the mature 
miRNA in the hairpin structure is also processed to a 
minor miRNA. A minor miRNA sequence has been 
identified for miR-126 and is designated MiR-126*. 
- ID: hsa-miR-126*, 
- miRBASE Accession #: MI0000444, 
- Sequence: The mature sequence for miR-126* is 14-
cauuauuacuuuugguacgcg-35. 
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Protein 
Note 
MicroRNAs are not translated to protein. 
Mutations 
Note 




Deregulation of miR-126 has been described in several 
solid and hematologic malignancies including lung, 
prostate, breast, renal cell, cervical, thyroid cancers and 
Acute Leukemias. Furthermore, it has been implicated 
in regulating processes fundamental to tumor 
development and progression. 
Lung cancer: non-small cell cancer 
Disease 
Several studies have demonstrated that miR-126 is 
reduced in lung cancer tissue compared to uninvolved 
adjacent lung tissue (Yanaihara et al., 2006). 
Prognosis 
A recent study examining miR-126 expression in 335 
lung cancer tissues revealed that elevated miR-126 
along with VEGF were negative prognostic factors. Of 
note, miR-126 expression was of significant predictive 
value in squamous histology and in cases with 
lymphatic metastases (Donnem et al., 2011). A separate 
study identified up-regulation of miR-126 in metastatic 
sites of lung cancer (Barshack et al., 2010). 
Therapeutic Implications: miR-126 represented one 
of a panel of miRNAs up-regulated in lung tumors 
from radiosensitive patients. Further investigation 
demonstrated that miR-126 could augment the 
apoptotic effects of irradiation in vitro (Wang et al., 
2011). 
Oncogenesis 
Tumor invasion and growth: miR-126 alters 
processes fundamental to tumor development and 
progression. In vitro gain of function reduced migrato y 
and invasive capacity as well as proliferation. The CRK 
adapter protein, VEGF and the miR-126 host gene 
EGFL-7 are potential functional targets (Crawford et 
al., 2008; Liu et al., 2009). 
Lung cancer: small cell cancer 
Oncogenesis 
MiR-126 gain of function in vitro reduced small cell 






In a cohort of 66 colorectal carcinomas, miR-126 
expression is reduced in colon cancer compared to 10 
adjacent non tumor tissues (Li et al., 2010). 
Oncogenesis 
MiR-126 has been shown to regulate the PI3-kinase 
signaling cascade through direct targeting of the 
p85beta subunit. This targeting resulted in an in vitro 




Diagnostic: MiR-126 represented one of several 
miRNAs whose expression distinguished myoepithelial 
breast cancer from basal type breast cancer 
(Bockmeyer et al., 2011). A separate study suggested 
that miR-126 may serve as a non-invasive biomarker 
for breast cancer. Patients with breast cancer had lower 
circulating levels of miR-126 when compared to 
normal controls (Wang et al., 2010). Lastly, analysis 
for miR-126 single nucleotide polymorphisms (SNPs) 
in a cohort of 6042 patients did not identify an 
associated breast cancer risk (Wang et al., 2010). 
Disease 
miR-126 has been shown to be down-regulated in 
breast cancer tissues. 
Oncogenesis 
Tumor growth and Metastasis: In vitro, high 
metastatic breast cancer cell lines had lower levels of 
miR-126. MiR-126 gain of function reduced both 
breast cancer cell growth in vitro and metastases in 
vivo. Furthermore, miR-126 expression was inversely 
correlated with presence of metastases in a cohort of 
breast cancer patients (Tavazoie et al., 2008). Insulin 
Receptor Substrate (IRS-1) has been implicated as a
functional target for miR-126 (Zhang et al., 2008). 
Gastric carcinoma 
Prognosis 
In a cohort of 100 patients with gastric cancer miR-126 
was one of a seven-miRNA signature that correlated 
with survival (Li et al., 2010). 
Oncogenesis 
In vitro, miR-126 reduced gastric cancer cell 
proliferation (Otsubo et al., 2011; Feng et al., 2010). 




Diagnostic: Early studies suggest that miR-126 
expression may have diagnostic utility in renal  
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carcinoma. In one study, miR-126 expression 
distinguished clear cell from renal cell carcinoma 
(Powers et al., 2011). 
Bladder cancer 
Note 
Diagnostic: Investigators examined urinary miRNA 
expression patterns in a cohort of patients (N=36) and
showed that the ratio of miR-126 to miR-152 could 
accurately diagnose bladder cancer with a specificity of 
82% and sensitivity of 72% (Hanke et al., 2010). 
Leukemia 
Note 
Diagnostic: Expression miRNA profiling in a cohort of 
47 primary AML specimens followed by qPCR 
validation revealed that miR-126 and miR-126* could 
be used to distinguish subgroups of AML with highest 
expression occurring in core-binding factor (CBF) 
AML. Allied in vitro and in vivo studies demonstrated 
that miR-126 could induce proliferation of murine bone 
marrow progenitor cells in the presence of the AML1-
ETO (AE) fusion gene (Li et al., 2008). The association 
between miR-126 and AML1/ETO rearrangements was 
further confirmed in a separate cohort of 29 AML 
samples (Cammarata et al., 2010). Low expression of 
miR-126 as part of a panel of miRNAs has been shown 
to correlate with CNS relapse in ALL (Zhang et al., 
2009). 
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